Bionomics Limited
(ASX:BNO) CEO & Managing Director Deborah Rathjen presents at ASX Spotlight New York and London about the discovery and development of biopharmaceuticals.
Bionomics has expanded from its Adelaide headquarters operations in San Diego and a subsidiary in Europe as the company partners with global pharmaceutical giant Merck & Co. (NYSE:MRK) to develop treatments for chronic pain.
Treatments for oncology and central nervous systems disorders will reach key data points in 2014 and experiments will continue into new methods of treating anxiety.
